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Abstract
Multiple myeloma (MM) is an incurable cancer that derives pro-survival/proliferative signals from the bone marrow (BM)
niche. Novel agents targeting not only cancer cells, but also the BM-niche have shown the greatest activity in MM. Histone
deacetylases (HDACs) are therapeutic targets in MM and we previously showed that HDAC3 inhibition decreases MM
proliferation both alone and in co-culture with bone marrow stromal cells (BMSC). In this study, we investigate the effects
of HDAC3 targeting in BMSCs. Using both BMSC lines as well as patient-derived BMSCs, we show that HDAC3
expression in BMSCs can be induced by co-culture with MM cells. Knock-out (KO), knock-down (KD), and pharmacologic
inhibition of HDAC3 in BMSCs results in decreased MM cell proliferation; including in autologous cultures of patient MM
cells with BMSCs. We identified both quantitative and qualitative changes in exosomes and exosomal miRNA, as well as
inhibition of IL-6 trans-signaling, as molecular mechanisms mediating anti-MM activity. Furthermore, we show that
HDAC3-KD in BM endothelial cells decreases neoangiogenesis, consistent with a broad effect of HDAC3 targeting in the
BM-niche. Our results therefore support the clinical development of HDAC3 inhibitors based not only on their direct anti-
MM effects, but also their modulation of the BM microenvironment.
Introduction
Multiple myeloma (MM) is a cancer of terminally differ-
entiated plasma cells that accounts for 1.3% of all malignancies
and 15% of hematological cancers, making it the second most
common blood cancer after non-Hodgkin lymphoma [1].
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Despite significant therapeutic advances with high dose ther-
apy and stem cell transplantation as well as novel therapies,
relapses occur in most patients and MM remains incurable. We
and others have shown that the bone marrow (BM) micro-
environment supports MM proliferation and survival, as well
as confers cell adhesion mediated-drug resistance (CAM-DR)
[2]. Our increasing understanding of MM biology has led to
the discovery of novel therapeutic targets such as histone
deacetylases (HDACs) in both tumor cells and BM milieu, and
the pan-HDAC inhibitor panobinostat has been FDA approved
to treat relapsed, refractory MM [3, 4]. However, clinical trials
have shown that nonselective HDAC inhibitors have narrow
therapeutic index, prompting the development of isoform-
specific HDAC inhibitors such as the HDAC6 inhibitor rico-
linostat, currently in clinical trials [5].
We previously showed that HDAC3-knockdown (KD) or
HDAC3-selective inhibition with BG45 attenuates MM pro-
liferation, both alone and in co-culture with bone marrow
stromal cells (BMSCs) [6]. There is a growing interest in
understanding the effects of novel drugs on the BM niche as it
has become increasingly evident that drugs targeting both
cancer cells and their microenvironment have been associated
with higher therapeutic success [7, 8]. In this study, we
investigated the effects of targeting HDAC3 in BMSCs and
BM endothelial cells (BMEC) on MM pathogenesis. We show
that HDAC3 knock-down (KD) and knock-out (KO) in both
human BM stromal cell lines and primary BMSCs derived
from patients with newly diagnosed (NDMM) and refractory
relapsed MM (RRMM) significantly decreased BMSC-
induced MM cell proliferation and survival in vitro and
in vivo. We further show that HDAC3 KD in BMSCs inhibits
cell adhesion mediated-drug resistance (CAM-DR) to doxor-
ubicin, and that HDAC3 KD in BMECs leads to a significant
inhibition of neo-angiogenesis. We studied the molecular
mechanisms mediating these phenotypes and discovered that
HDAC3 KD in BMSC causes increased secretion of soluble
glycoprotein 130 (sgp130), which results in dysregulation of
IL-6 trans-signaling, a well-established pro-survival pathway in
MM. By using proteomics and micro RNA (miRNA)
sequencing, we detected changes in exosomes derived from
HDAC3 KD versus scramble control co-culture systems [9].
Altogether, our study supports the clinical development of
HDAC3 inhibitors based not only on their direct, anti-MM
effect, but also on their indirect effects on the BM milieu,
resulting in decreased MM cell growth and survival.
Materials and methods
siRNA transfection and HDAC3 overexpression
siRNAs against HDAC3 were purchased from Dharma-
con™ (GE Healthcare Life Sciences, Marlborough, MA,
USA). For siRNA transfection of BMSCs, Lipofectamine
RNAiMax (Thermo Fisher Scientific, Waltham, MA, USA)
was used. For siRNA transfection of CD138− BMMCs, the
NEON® transfection system (Thermo Fisher Scientific)
was used.
In order to overexpress HDAC3, HS-5 cells were tran-
siently transfected with HDAC3-Flag tagged protein using
Lipofectamine 2000 (Thermo Fisher Scientific) according to
the manufacturer’s protocol. HDAC3-Flag was a gift from
Eric Verdin (Addgene plasmid # 13819).
ON-TARGETplus non-targeting control
siRNA # Catalog number Target sequence Abbreviated as
1 D-001810-01-05 NA Scramble
ON-TARGETplus human HDAC3
siRNA # Catalog number Target sequence Abbreviated as
1 J-003496-09 AAAGCGAUGU
GGAGAUUUA
HDAC3 #1
3 J-003496-11 GGAAUGCGU
UGAAUAUGUC
HDAC3 #3
CRISPR-cas9 knockout of HDAC3
We designed single guide RNA (sgRNA) targeting
hsHDAC3 by using MIT CRISPR tool. HDAC3 sgRNA
was then cloned into pSpCas9(BB)-2A-GFP vector, as
previously reported [10]. Positive monoclones were
screened via western blot based on absent HDAC3
expression. Bi-allelic KO was confirmed via genomic PCR
and TA-cloning of target gene locus. The following sgRNA
against exon 1 of HDAC3 was used: TATTTCTAC-
GACCCCGACGT. pSpCas9(BB)-2A-GFP (PX458) was a
gift from Feng Zhang (Addgene plasmid # 48138).
Luciferase proliferation assay
BMSC were transfected with HDAC3 siRNA, HDAC3
overexpression vector or treated with BG45 for the indi-
cated times. After 48–96h, media was removed and cells
washed prior to adding MM1S.Luc or H929.Luc for a
further 48–96h. Proliferation was measured using the
Luciferase assay according to manufacturer’s protocol
(Promega, Madison, WI, USA).
Murine xenograft models
Five-week-old female severe combined immunodeficiency-
beige (SCID-beige) mice were used for this study. All
animal studies were performed under a protocol approved
by the Animal Ethics Committee of the DFCI. Mice were
subcutaneously injected with a co-culture of 5 × 106 viable
MM1S.Luc and 5 × 106 viable HS-5 (HDAC3 WT or
HDAC3 KO) cells in a 1:1 ratio with Matrigel™
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(Invitrogen, Carlsbad, CA, USA). MM1S.Luc tumor burden
was measured weekly using whole-body bioluminescence
imaging (BLI). Mice were sacrificed when the tumor
reached 2 cm in length or 2 cm3 volume or if mice appeared
moribund, to prevent unnecessary morbidity.
Statistical analysis
Experiments were performed at least three times unless
otherwise specified. Biological triplicates were used unless
otherwise specified. Statistical significance was determined
by Student’s t-test after determination of normal distribution
with F-test. (NS: P > 0.05; *P ≤ 0.05; **P ≤ 0.01; ***P ≤
0.001; ****P ≤ 0.0001).
Results
BMSC derived from MM patients have increased
expression of HDAC3 which results in enhanced MM
cell proliferation
First, we sought to determine the relative expression of
HDAC3 in the CD138− BMMC fraction versus the CD138+
(plasma cell) BMMC fraction. Gene expression analysis from
the IFM/DFCI 2009 dataset showed that CD138− BMMCs
had higher expression of HDAC3 compared to CD138+
BMMCs (Fig. 1a). Consistent with this data, western blot
analysis showed that HDAC3 is more highly expressed in the
HS-5 bone marrow stromal cell line compared to MM.1S
MM cell line (Fig. S1a), leading us to hypothesize that tar-
geting HDAC3 in stroma could potentially have a profound
impact on the MM survival and proliferation in the context of
the BM microenvironment.
Next, to investigate whether co-culture of MM and BMSC
would lead to changes in expression of HDAC3 in either cell
type, we cultured luciferase expressing MM.1S cells (MM1S.
Luc) on a monolayer of HS-5 BMSC line, followed by
magnetic bead selection for CD138+ MM cells. Our data
show that co-culture induces increased HDAC3 expression in
HS-5 BMSCs, but not in MM1S.Luc cells (Figs. 1b, S1b).
Consistent with this data, gene expression profiling show that
co-culture with HS-5 does not alter HDAC3 expression in a
panel of MM cell lines (Fig. S1c). Importantly, BMSC
derived from MM patients (MM-BMSC) express higher
levels of HDAC3, as assessed by western blotting, compared
to healthy donor BMSC (HD-BMSC) (Fig. S1d), further
corroborating the in vitro finding that HDAC3 expression in
BMSCs can be induced by MM cells.
To functionally assess whether increased HDAC3
expression in BMSC results in enhanced MM proliferation/
viability, we transiently overexpressed FLAG-tagged
HDAC3 (HDAC3-OE) in HS-5 BMSCs. MM1S.Luc cells
proliferation was increased in co-culture with HDAC3 OE
HS-5 BMSCs compared to cultures with HS-5 transfected
with an empty, backbone vector (BB) (28% increase in MM
proliferation; P value < 0.05) (Fig. S2a, S2b).
HDAC3 is not essential for BMSC and BMEC survival
or proliferation, but HDAC3 KD increases MM to
BMSC chemotaxis and inhibits neo-angiogenesis
Next, we asked whether HDAC3 expression is necessary for
BMSC survival. siRNA-mediated HDAC3 KD as well as
monoallelic (clone #56) and biallelic (clone #54) HDAC3
KO show that HDAC3 does not impact BMSC viability
(Figs. S3a–d, 1c, S4). Similarly, pharmacological inhibition
of HDAC3 using the HDAC3-selective inhibitor BG45 does
not trigger significant BMSC growth inhibition, even at
concentrations up to two-fold higher than the EC50 for
MM.1S cells (Figs. 1d, S3e). However, HDAC3 KD in HS-
5 BMSCs triggered increased MM chemotaxis (Fig. S5a).
Based on our cytokine profiling data, we hypothesized that
this phenotype was mediated by increased CXCL1 (GRO-
alpha) (Fig. S5b). To test this hypothesis, we used anti-
CXCL1 neutralizing antibody (15 µg/ml) in migration
assays and show that it abrogates MM transmigration
towards HDAC3 KD HS-5 cells (Fig. S5a).
Similar to BMSCs, HDAC3 silencing in BMECs only
modestly decreases their viability (Fig. S6). However,
HDAC3 KD significantly inhibits endothelial tube forma-
tion, indicating that HDAC3 function in BMECs is neces-
sary for adequate neo-angiogenesis (Fig. 1e) [11].
Targeting HDAC3 in BMSC decreases BMSC-induced
MM cell line and primary MM cell proliferation
To evaluate the effect of HDAC3-silencing in HS-5 BMSCs
on MM proliferation, we co-cultured MM1S.Luc and H929.
Luc MM cells for 4 days with HS-5 BMSCs previously
transfected with HDAC3 siRNA or scrambled siRNA and
assessed MM cell proliferation using luciferase assay
(Fig. 2a). HDAC3 KD significantly inhibits MM1S.Luc and
H929.Luc MM cell proliferation (36.1% and 27.2% mean
decrease, respectively, P value < 0.05) (Figs. 2b, S7a). A
similar pattern of reduction in MM proliferation is observed
when HDAC3 KD was performed in MSP-1 cells, a MM-
BMSC-derived cell line (14% decrease, P value < 0.05)
(Fig. S7b). To assess whether KD of other HDAC class I
members results in similar anti-proliferative effects, we
performed HDAC1 and HDAC2 KD in HS-5 BMSCs prior
to co-culture with MM cell lines. Our results show that
HDAC1 KD had no effect on MM proliferation, while
targeting HDAC2 increases MM proliferation (Fig. S8a,
S8b). As an alternative strategy to target HDAC3, we also
used HDAC3 monoallelic and biallelic KO HS-5 BMSC
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clones. Significant reduction in MM1S.Luc proliferation
was noted in co-cultures with these mono and bi-allelic KO
HS-5 cells compared to co-culture with HDAC3 WT HS-5
cells (Fig. 2c). A significant reduction in H929.Luc pro-
liferation was also observed in co-culture with bi-allelic KO
HS-5 cells (Figs. 2c, S7c).
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Fig. 1 HDAC3 expression is increased in MM-derived BMSC com-
pared to healthy donor-derived BMSC but HDAC3 is not necessary
for BMSC viability or proliferation. a Gene expression analysis from
the IFM/DFCI 2009 dataset revealed that HDAC3 expression is higher
in CD138− BMMCs when compared to CD138+ BMMCs derived
from patients with MM. b Co-culture of HS-5 cells with MM1S.Luc
triggers induction of HDAC3 expression in BMSC. GAPDH was
used as loading control. Quantification was performed using ImageJ.
c HDAC3 KO HS-5 cells have comparable viability to HDAC3 WT
HS-5 cells as assessed by CCK-8 assay. d HDAC3 inhibition using
BG45 is not cytotoxic towards HS-5 even at doses two-folds higher
than the Ec50 of MM1S as measured by CCK-8 assay at 96 h.
e Endothelial tube formation assay shows compromised formation of
endothelial tubes in BMEC60 cells transfected with HDAC3 siRNA
compared to scrambled siRNA. Two representative, independent
experiments shown
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Pharmacological inhibition of HDAC3 (Fig. S8c) in HS-5
BMSCs via BG45 decreases MM proliferation when com-
pared to MM cells cultured with DMSO-treated HS-5 cells
(18% decrease, P value < 0.05) (Fig. S9a). We confirmed that
HDAC3 inhibition persisted during these co-cultures based
upon expression of acetylated-H3K9 (Fig. S9b).
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Moreover, HDAC3 KD in MM-BMSC obtained from
patients with newly-diagnosed MM (NDMM; N= 3) and
refractory-relapsed MM (RRMM; N= 6) also significantly
decreases BMSC-induced MM1S.Luc proliferation in the co-
culture system (Figs. 3a, b, S10a, S10b). As a negative
control we used healthy donor-derived BMSCs (HD-BMSC),
which do not express HDAC3 (Fig. S1d, S10c). Consistently,
HDAC3 KD in HD-BMSC does not affect MM1S.Luc cell
proliferation in the co-culture system (Fig. S10c). Impor-
tantly, we demonstrate that HDAC3 KD (but not scrambled
siRNA KD) in primary CD138− BMMCs significantly
decreases proliferation of autologous CD138+ MM cells
derived from a patient with RRMM (Figs. 3c, S11a–c).
Paracrine-autocrine loop between HDAC3 KD BMSC
and MM cells leads to inhibition of IL-6 trans-
signaling
Next, we asked whether the observed anti-MM proliferative
effect of HDAC3 KD/KO in BMSC was due to impaired
MM-BMSC adhesion. However, adhesion assays showed
no significant changes in MM-BMSC adhesion between
scrambled vs HDAC3 KD HS-5 cells (Fig. S12a, S12b).
Having excluded diminished cell-to-cell contact as a
potential molecular mechanism, we next investigated auto-
crine/paracrine factors that could impact MM proliferation
and viability in co-cultures. To this end, we harvested
conditioned media (CM) from the co-cultures of HDAC3
KD versus scrambled siRNA HS-5 BMSCs with MM1S.
Luc cells and used it as culture medium for MM1S.Luc
alone. CM obtained from HDAC3 KD HS-5 and MM1S.
Luc co-cultures significantly inhibited MM1S.Luc pro-
liferation (31.2% mean decrease, P value < 0.05) compared
to CM obtained from scrambled siRNA KD HS5 co-
cultured with MM1S.Luc (Fig. 4a). Consistent with this,
CM obtained from the co-culture of HDAC3 KD HS-5 and
H929.Luc significantly inhibited H929.Luc proliferation
(Fig. S13a) and CM obtained from the co-culture of
HDAC3 KD NDMM-derived BMSC and MM1S.Luc sig-
nificantly inhibited MM1S.Luc proliferation (Fig. S13b).
Interestingly, CM from HDAC3 KD HS-5 or NDMM-
derived BMSC cells alone failed to show an anti-
proliferative effect, suggesting paracrine-autocrine loop
between HDAC3 KD BMSC and MM cells alters the
secretome in a way that decreases the proliferative advan-
tage induced by the microenvironment (Fig. S13c, S13d).
Cytokine profiling showed a 1.8-fold increase in soluble
glycoprotein 130 (sgp130), a natural inhibitor of the IL6-
transignaling pathway, in co-culture supernatants from
HDAC3-KD HS-5 compared to scrambled siRNA HS-5;
which was confirmed by ELISA (Figs. 4b, S14a, S14b).
Consistent with this data, ELISA performed on co-culture
supernatants from HDAC3-silenced primary BMSCs
derived from two patients with MM (one in partial remis-
sion, and the other RRMM) showed a 1.6-fold and 1.5-fold
increase in sgp130 respectively (Fig. 4b). To establish the
source of the increased sgp130, MM1S.Luc cells were first
co-cultured with HDAC3 KD or scrambled siRNA HS-5
cells, and then magnetically separated using CD138+ beads
prior to RNA extraction in both the positive and negative
fractions, respectively. RT-PCR showed a 1.3-fold increase
in gp130 mRNA in MM1S.Luc cells (CD138 positive
fraction) that were co-cultured with HDAC3 KD but not
scrambled HS-5 (Fig. S15a). However, gp130 mRNA level
in HS-5 cells (CD138 negative fraction) was comparable
between the HDAC3 KD and scrambled groups (Fig. S15a).
These data suggest that MM cells, and not BMSCs, are the
source of increased gp130 secretion in co-culture system.
Flow-cytometric analysis showed no changes in surface-
bound gp130 (also known as CD130) in MM cells and HS-
5 cells after co-culture, regardless of HDAC3 expression,
suggesting that CD130 shedding from MM cells may also
contribute to increased sgp130 in HDAC3 KD plus MM
cell co-cultures (Fig. S15b, 15c).
Inhibition of the IL6-transignalling pathway is
necessary and sufficient to drive HDAC3 KD BMSC-
induced MM proliferation arrest
Next, we co-cultured scramble siRNA HS-5 and MM1S.
Luc cells in the presence or absence of exogenous human
recombinant sgp130 and showed that adding sgp130 to the
media was sufficient to block HS-5-induced MM pro-
liferation (Fig. 4c). Vice versa, co-culture of HDAC3 KD
HS-5 cells with MM1S.Luc cells in the presence or absence
of IL-6/IL-6R protein chimera, the ligand for both cell
Fig. 2 HDAC3 knockdown (KD) and knockout (KO) in BMSCs
triggers significant MM cell growth inhibition in MM-BMSC co-cul-
ture setting. a Co-culture experiment schema and western blot showing
HDAC3 siRNA knockdown in HS-5 cells after 48 h of transfection.
HDAC3 was silenced in HS-5 BMSCs using siRNA for 48 h. The
transfection mix was subsequently washed out and MM1S.Luc/H929.
Luc was added in co-culture for a further 4 days before luciferase was
performed to measure MM proliferation. The HDAC3 KD in HS-5
cells persists up to 96 h after transfection mix is washed out. GAPDH
is used as a loading control. b HDAC3 siRNA knockdown in HS-5
significantly inhibits MM1S.Luc proliferation as measured by Luci-
ferase Assay (left chart: 37.1% mean decrease in MM1S.Luc pro-
liferation when cocultured with HDAC3 KD HS-5, P < 0.05).
HDAC3 siRNA KD in HS-5 significantly inhibits H929.Luc pro-
liferation as measured by Luciferase Assay (right chart: 27.2% mean
decrease in H929.Luc proliferation when cocultured with HDAC3 KD
HS-5, P < 0.05). c Left chart: Homozygous HDAC3 KO HS-5 clone
#54 inhibited the proliferation of MM1S.Luc to a greater extent than
heterozygous HDAC3 KO HS-5 clone #56 when compared to HDAC3
WT HS-5 clone. Right chart: Homozygous HDAC3 KO HS-5 clone
#54 inhibited the proliferation of H929.Luc compared to HDAC3 WT
HS-5 clone
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surface CD130 and decoy receptor sgp130, showed that
IL-6/IL-6R was sufficient to rescue HDAC3 KD-mediated
MM growth arrest (Fig. 4d). Finally, siRNA KD of CD130
in MM1S.Luc cells caused profound cytotoxicity, suggest-
ing that the IL-6 trans-signaling pathway is necessary for
MM survival (Fig. 4e). Altogether, these data suggest that
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increased level of sgp130, a natural inhibitor of the IL6-
trans-signaling pathway may account, at least in part, for
HDAC3 KD BMSC-induced MM proliferation arrest.
Consistent with inhibition of the IL-6 trans-signaling path-
way, western blot analysis of MM1S.Luc cells co-cultured
with HDAC3 KD cells showed downregulation of p-STAT3
and p-RB1, with a reciprocal increase of p21 when com-
pared to MM1S.Luc cells co-cultured with scrambled HS-5
BMSC, without changes in ERK and AKT (Fig. S16).
Interestingly, soluble IL-6R was also increased in the
supernatant of HDAC3 KD HS-5 co-cultured with MM1S.
Luc cells, and exogenous IL-6 was sufficient to rescue
HDAC3 KD-mediated MM cell growth inhibition (Figs. 4f,
S14a, S14b). Potential mechanisms of this rescue effect
include activation of the canonical IL-6 pathway and/or
increased IL-6/IL-6R formation. Consistent with published
data that increased IL-6 signaling is a mechanism of dox-
orubicin resistance in MM, HDAC3-silencing in HS-5 cells
attenuates cell adhesion mediated drug resistance (CAM-
DR) against doxorubicin, but not bortezomib or lenalido-
mide (Fig. S17a, S17b) [12].
HDAC3 KD in HS-5 BMSC leads to quantitative
changes in exosomes via a paracrine/autocrine loop
contributing to MM cell growth arrest
As exosomes have been shown to play a role in MM
pathogenesis, we next asked whether they play a role in
mediating HDAC3 KD BMSC-induced MM proliferation
arrest. To this end, we performed exosome enrichment from
conditioned media obtained from co-culture of MM1S.Luc
cells with HDAC3 KD versus scramble siRNA HS-5 cells.
Quality of enrichment for exosomes was confirmed using
western blot and nanoparticle tracking analysis (NTA)
(Fig. 5a, S18a). We observed a 20% decrease in the quantity
of exosomes secreted in HDAC3 KD versus scrambled
siRNA HS-5 co-culture supernatants, suggesting that
HDAC3 KD in HS-5 cells leads to a reduction in exosome
secretion in co-culture systems (Fig. 5a). When comparing
NTA profiles, we discovered that HDAC3 KD in HS-5
BMSC markedly decreased small exosome vesicles (Exo-S,
60–80 nm), while sparing large exosome vesicles (Exo-L,
~120 nm) (Fig. 5a). Consistent with the MM-BMSC para-
crine-autocrine signaling hypothesis, HDAC3 KD in HS-5
BMSC alone did not show any quantitative change in
exosome secretion when compared to scramble siRNA HS-
5 BMSC, further supporting the paracrine-autocrine nature
of this crosstalk (Fig. S18b–d).
To define the molecular mechanisms underlying the
quantitative changes observed in the exosome pool, we
performed proteomic profiling of cell lysates from MM1S.
Luc cells co-cultured with either HDAC3-silenced or
scramble siRNA HS-5 cells (Table S1; Fig. S19a–c).
Interestingly, the expression of tumor susceptibility gene
101 (TSG101), a protein relevant in exosome biogenesis, is
induced in MM1S.Luc by co-coculture with scramble
siRNA HS-5 cells (Fig. S18e). However, HDAC3 KD in
HS-5 prior to co-culture completely abrogates BMSC-
induced TSG101 induction in MM1S.Luc (Table S1;
Fig. S18e). To assess whether downregulation of TSG101 is
sufficient to reduce exosome secretion, we performed
TSG101 KD in the MM cell lines MM.1S and RPMI-8226
(Figs. 5b, S18f). Our data show that TSG101 KD in both
MM.1S and RPMI-8226 leads to reduced Exo-S secretion.
Altogether, these data suggest that HDAC3-KD in HS-5
BMSC inhibits BMSC-induced upregulation of TSG101 in
MM cells, resulting in decreased exosome release.
HDAC3 KD in HS-5 BMSC leads to qualitative
changes in exosomes via a paracrine/autocrine loop
contributing to MM cell growth arrest
In order to assess qualitative changes in exosomes, we next
cultured MM cells in the presence of 50ug/ml exosomes
harvested and enriched from either HDAC3 KD or scram-
bled siRNA HS5-MM co-cultures. First, we confirmed
exosome internalization in MM cells via confocal micro-
scopy and flow-cytometry (Fig. S20a, S20b). Next, we
observed 2.5-fold increased proliferation in MM cells cul-
tured in the presence of exosomes derived from scramble
HS5-MM co-cultures, compared to MM cells alone
(Fig. 5c). However, this proliferative burst was abrogated
by 66% when MM cells were cultured with exosomes
derived from HDAC3 KD HS5-MM co-cultures (P value <
0.05, Fig. 5c). These data indicate that HDAC3-silencing in
HS-5 BMSCs leads to qualitative changes in exosomes
derived from BMSC-MM co-cultures, which result in
decreased MM proliferation.
Fig. 3 HDAC3 knockdown (KD) in primary human BM stromal cells
derived from newly-diagnosed MM (ND BMSC), and refractory-
relapsed MM (RR BMSC) trigger significant MM cell growth inhi-
bition in MM-MSC co-culture setting. a Figure comparing MM1S.Luc
proliferation in co-culture with scramble (left) or HDAC3 si-RNA
transfected (right) newly diagnosed (ND, black dots) and refractory
relapsed (RR, red squares) BMSC respectively. b Light microscopy
images (left) showing the co-culture of MM1S.Luc with scramble or
HDAC3 KD BMSCs and fluorescent microscopy images (right)
showing mCherry-labeled MM1S.Luc cells co-cultured with scramble
or HDAC3 KD BMSCs derived from RR MM (RR BMSC #1). c Dot
plot panels show the relative proportion of CD138 negative bone
marrow mononuclear cells (BMMC, top rectangle) and CD138 posi-
tive MM cells (lower oval) over indicated times in an autologous co-
culture system of primary cells obtained from a patient with RRMM.
Top panels represent scrambled-transfected CD138 negative, bone
marrow mononuclear cells (BMMC), lower panels show HDAC3
siRNA-transfected BMMC. d Chart representing fold changes in MM
cell proportion over indicated times in scrambled-transfected and
HDAC3 siRNA-transfected BMMC co-culture
Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma. . . 203
Content courtesy of Springer Nature, terms of use apply. Rights reserved
Fig. 4 Conditioned supernatant from HDAC3 KD HS-5 plus MM1S.
Luc co-culture triggers significant MM cell growth inhibition through
the attenuation of IL-6 trans-signaling. a Conditioned media (CM)
from HDAC3 KD HS-5 and MM1S.Luc co-culture inhibits MM1S.
Luc proliferation when compared to CM from the co-culture of
scrambled HS-5 and MM1S.Luc (31.2% mean decrease in MM1S.Luc
proliferation in HDAC3 KD, P < 0.05). b ELISA for soluble-gp130
(sgp130) shows increase in sgp130 in the co-culture supernatant of
HDAC3-silenced HS-5 (1.8-fold), and HDAC3-silenced primary
BMSCs derived from a patient with MM in partial remission (1.6-fold)
and RRMM (1.5-fold), respectively. c Treatment with 2 µg/ml of
exogenous human recombinant sgp130 abrogates HS-5 induced
MM1S.Luc proliferation while d treatment with 20 ng/ml of human
recombinant IL6/IL6R chimera rescues MM1S.Luc growth inhibition
induced by HDAC3-silencing in HS-5. e Silencing of CD130 in
MM1S.Luc results in significant cell death as measured by PI/Annexin
V apoptosis assay. Western blot showing CD130 KD via three inde-
pendent shRNAs. GAPDH was used as loading control. f IL-6 alone
was also able to rescue MM1S.Luc growth inhibition induced by
HDAC3-silencing in HS-5
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Exosomes derived from HDAC3 KD BMSC show
downregulation of pro-survival microRNA (miR)
miR380, miR382, miR15b, miR9986, and miR5191
We next performed small RNASeq on exosomes isolated
from the conditioned supernatant of MM1S.Luc cells alone,
HDAC3 KD HS-5-MM1S.Luc co-culture, or scrambled
siRNA HS-5-MM1SLuc co-culture. Compared to MM cells
alone, exosomes from MM1S.Luc cells co-cultured with
scrambled HDAC3 HS-5 showed increased expression of a
set of miRs which are known to exert a pro-survival func-
tion; including miR380, miR382, miR15b, miR9986, and
Fig. 5 Qualitative and quantitative changes in exosomes derived from
HDAC3 KD HS-5 plus MM1S.Luc co-culture supernatant contributes to
MM cell growth arrest. a Nanoparticle tracking analysis (NTA) showing
the mean/modal size and concentration of exosomes in the supernatant of
HDAC3 KD HS-5 versus scramble HS-5, co-cultured with MM1S.Luc.
The data was normalized to cell count for each condition. b siRNA
knockdown of TSG101 in MM.1S resulted in decreased exosome
secretion as measured by NTA. Data was normalized to cell count for
each condition. c Exosomes isolated from HDAC3-silenced HS-5 trig-
gers significant MM1S.Luc growth inhibition compared to exosomes
isolated from scramble siRNA HS-5 (65.7% decrease in MM1S.Luc
proliferation in HS-5 (HDAC3 KD) alone, P < 0.05)
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miR5191. Importantly, upregulation of these miRs was
partially abrogated in HDAC3 KD HS-5-MM co-culture
(Fig. S21a, S21b). Taken together, these data indicate that
HDAC3 KD in HS-5 cells leads to downregulation of pro-
survival miRNAs in exosomes obtained from BMSC-MM
co-culture systems.
HDAC3 KO in HS-5 abrogates BMSC-induced
proliferation of MM cells in a 3D-in vitro co-culture
model and significantly impairs tumor growth
in vivo
To mimic the MM BM niche, MM1S.Luc cells were co-
cultured with HDAC3 WT or KO HS-5 cells in a hydrogel
3D in vitro co-culture system. As expected, WT HS-5 cells
induced a 1.4-fold increase in MM1S.Luc proliferation
when compared to MM cells alone. However, this effect
was completely abrogated when MM1S.Luc cells were co-
cultured with HDAC3 KO HS-5 cells (P value < 0.05,
Fig. 6a). These data suggest that targeting HDAC3 in
BMSC leads to significant abrogation of BMSC-induced
MM proliferation in a 3D system.
To evaluate the translational significance of our findings,
we inoculated immunodeficient mice subcutaneously with a
1:1:1 mix of MM1S.Luc cells, Matrigel and either HDAC3
WT or KO HS-5 cells. At four weeks post inoculation, mice
bearing HDAC3 KO tumor showed impaired engraftment
(50% vs. 25% non-engrafted tumor in HDAC3 KO and
HDAC3 WT group, respectively) and decreased tumor
burden (mean total flux 1.1e7 vs. 2.9e9 in HDAC3 KO and
WT, respectively), (Figs. 6b, c). Longitudinal follow-up of
mice revealed that HDAC3 KO HS-5-tumor bearing ani-
mals had statistically significant longer survival compared
to HDAC3 WT HS-5 tumor bearing animals (median OS 60
vs. 70 days; HDAC3 WT vs. HDAC3 KO respectively, P
value= 0.009; hazard ratio for death 0.13 KO vs. WT)
(Fig. 6d). These data support a role for HDAC3 targeting in
BMSC as a novel strategy to impact MM survival and
proliferation in vivo.
Discussion
Unlike solid tumors where primary and metastatic disease
occur in separate and distinct sites, MM is characterized by
the widespread involvement of multiple sites within the BM
microenvironment [13]. It is well established that, through
bi-directional signaling loops, the BM microenvironment
induces MM cell proliferation, survival, drug resistance,
and dissemination [13–15]. Indeed, agents most effective in
the treatment of MM not only target cancer cells but also the
BM niche, including immunomodulatory drugs and pro-
teasome inhibitors [8, 16, 17]. Identifying novel agents
exerting anti-MM activity in the context of the BM niche is
therefore crucial in developing effective therapies. We have
previously shown that the HDAC3-selective inhibitor BG45
inhibits MM proliferation [6, 18]. To date, however, the
biological impact of HDAC3 inhibition in the context of the
BM microenvironment has not yet been fully elucidated.
We here therefore examined whether HDAC3 inhibition in
the BMSC compartment could exert an indirect effect on
MM cells.
Neo-angiogenesis is a major determinant of MM pro-
gression, dissemination, and drug resistance. Previous
reports have shown that HDAC inhibitors inhibit angio-
genesis by attenuating endothelial tube formation; however,
the specific HDAC isoform(s) that mediate this effect have
not been defined [11, 19, 20]. Importantly, our study shows
that HDAC3 KD in BMEC abolishes endothelial tube for-
mation, suggesting that this isoform is relevant in support-
ing neo-angiogenesis in the MM BM niche.
We then focused our attention to BMSCs. First, we
observed that HDAC3 expression is increased in MM
patient-derived BMSC compared to healthy donor-derived
BMSC, and that HDAC3 expression in BMSC can be
induced by MM co-culture in vitro. By using BMSC lines
and patient cells, including autologous BMSC and MM
cells, we show that targeting HDAC3 via KD, KO, or
pharmacological inhibition results in decreased MM cell
proliferation. Focusing on the secretome of MM-BMSC co-
culture systems, we identified increased sgp130 and con-
sequent inhibition of IL6 trans-signaling pathway as a major
molecular mechanism driving HDAC3 KD HS-induced
MM proliferation arrest. Previous studies have reported
sgp130 to be the natural inhibitor of the IL-6 trans-signaling
pathway, a pathway that we and others have shown to
mediate MM proliferation [9, 21]. Specifically, the IL-6
trans-signaling pathway involves the binding of IL-6 with
soluble IL6R to form the IL6/IL-6R complex. The complex
can then binds to CD130 on MM cells to activate down-
stream STAT3 signaling which in turns mediates MM cell
survival and proliferation [21]. Conversely, sgp130 acts as a
decoy receptor to prevent binding of the IL-6/IL-6R com-
plex to membrane CD130, thereby inhibiting downstream
STAT3 signaling and MM cell proliferation (Fig. 7) [21].
Consistent with this mechanism, our results demonstrate
that: CD130 knockdown was profoundly cytotoxic to MM
cells; excess sgp130 is sufficient to recapitulate HDAC3
KD HS-5 induced growth arrest; and inhibition of IL6 trans-
signaling is necessary to mediate HDAC3 KD HS-5
induced growth arrest.
Together with cytokines, exosomes are the main soluble
mediators of intercellular communication. Previous reports
showed that exosomes derived from both BMSCs and MM
are able to promote MM growth [22–24]. In this study,
we show that exosome secretion is reduced in HDAC3 KD
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HS5-MM co-cultures due to downregulation of TSG101 in
MM. TSG101 is an integral component of endosomal sorting
complex required for transport (ESCRT) complex, which
drives exosome biogenesis and is a recognized exosome
marker [25]. We and others have previously reported that
silencing of TSG101 results in reduced exosome secretion
[25, 26]. Importantly, recent studies have revealed that exo-
somes are able to mediate the intercellular exchange of
Fig. 6 HDAC3 expression in BMSC is essential for its MM growth-
supporting effects both in a 3D-in vitro co-culture model and in vivo. a
MM1S.Luc proliferation in a 3D system alone or in co-culture with
WT or HDAC3 KO HS-5. b Bioluminescence imaging of mice
inoculated subcutaneously with MM1S.Luc cells and WT (left panels)
or HDAC3 KO (right panels) HS-5. Five representative mice per group
are shown. c Luciferase activity of tumor in each cohort was quantified
using the Living Image software. Data represent mean ± s.d. (P value
> 0.05). d The overall survival of mice inoculated with HDAC3 KO
HS-5 plus MM1S.Luc was significantly higher compared to mice
inoculated with WT HS-5 plus MM1S.Luc (median OS: 70 (WT) vs.
60 (KO) days; P= 0.0094) (N= 8 each group)
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miRNAs in the context of the MM BM microenvironment
[27]. In our study, exosome miRseq revealed a decrease in
the exosomal expression of miR380 and miR382 when
HDAC3 was silenced in BMSCs. miR380 has been reported
to attenuate p53 signaling, while miR382 has been reported
to be more highly expressed in patients with MM, suggesting
a pathogenetic function of these miRNAs [28, 29].
To further validate the potential clinical significance of
our findings, we next used a 3D in vitro system to show that
HDAC3 KO in BMSCs significantly impacts MM cell
proliferation in the co-culture setting. Finally, we show that
HDAC3 KO in BMSC impairs tumor engraftment and
growth in a murine xenograft model of human MM, further
supporting the potential clinical utility of HDAC3 inhibition
to target MM cells in the context of the BM niche.
In summary, we have previously shown that targeting
HDAC3 directly impacts MM cell survival, and here pro-
vide a phenotypic and molecular characterization of the
effects of targeting HDAC3 in the MM BM niche. By using
in vitro and in vivo models, we show that disrupting
HDAC3 signaling in BM accessory cells negatively affects
MM growth and survival in the MM BM microenviron-
ment. This is the first report of the isolated effects of
HDAC3 targeting in BM accessory cells, showing such an
indirect antitumor effect. Most importantly, our study fur-
ther supports the clinical development of drugs targeting not
only tumor cells, but also the microenvironment, in an effort
to limit drug resistance and increase therapeutic efficacy.
Our results therefore provide the preclinical rationale for
clinical trials targeting HDAC3 in BMSCs to indirectly
inhibit tumor cell growth, survival, and drug resistance in
the BM milieu and thereby improve patient outcome.
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Fig. 7 Schema of proposed
molecular mechanisms
underlying anti-MM effect of
HDAC3 targeting in BMSC. On
one hand, HDAC3 targeting in
BMSC has anti-MM effect by
increasing sgp130 secretion, via
a paracrine-autocrine loop,
which acts as a decoy receptor to
prevent binding of the IL6/IL6R
complex to CD130. The
resulting abrogation of IL-6
trans-signaling and downstream
STAT3 signaling leads to
decreased MM proliferation. On
the other, HDAC3 silencing in
BMSCs leads to decreased
exosome secretion associated to
downregulation of TSG101 and
qualitative changes in miRNA
content, resulting in MM growth
inhibition
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